2/10
07:14 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/10
07:13 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/9
09:04 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
2/9
07:20 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/8
08:56 pm
roiv
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum [Yahoo! Finance]
Medium
Report
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum [Yahoo! Finance]
2/7
06:48 am
roiv
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress [Yahoo! Finance]
Medium
Report
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress [Yahoo! Finance]
2/6
10:01 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/6
07:12 pm
roiv
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
2/6
02:13 pm
roiv
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
Low
Report
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
2/6
01:26 pm
roiv
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript [Seeking Alpha]
2/6
10:36 am
roiv
Roivant Sciences Q3 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Roivant Sciences Q3 Earnings Call Highlights [Yahoo! Finance]
2/6
09:07 am
roiv
Pfizer – Roivant tie-up generates positive mid-stage data for lead asset [Seeking Alpha]
Medium
Report
Pfizer – Roivant tie-up generates positive mid-stage data for lead asset [Seeking Alpha]
2/6
08:11 am
roiv
Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment [Yahoo! Finance]
Low
Report
Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment [Yahoo! Finance]
2/6
07:10 am
roiv
Roivant Sciences GAAP EPS of -$0.38 misses by $0.07, revenue of $1.99M misses by $4.15M [Seeking Alpha]
High
Report
Roivant Sciences GAAP EPS of -$0.38 misses by $0.07, revenue of $1.99M misses by $4.15M [Seeking Alpha]
2/6
07:00 am
roiv
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
High
Report
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
2/6
07:00 am
roiv
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
High
Report
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
2/6
07:00 am
roiv
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
High
Report
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
1/29
03:51 am
roiv
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth [Seeking Alpha]
Low
Report
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth [Seeking Alpha]
1/23
04:15 pm
roiv
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Low
Report
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
1/2
10:56 am
roiv
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline [Yahoo! Finance]
Low
Report
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline [Yahoo! Finance]
12/20
05:46 pm
roiv
Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
Low
Report
Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
12/18
09:09 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/18
03:09 am
roiv
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
Medium
Report
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
12/15
02:30 pm
roiv
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
12/15
12:58 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.